Publications by authors named "L Lumbroso-Le Rouic"
Article Synopsis
- Retinoblastoma is the most common eye cancer in children, originating from developing retinal cells, but its molecular behavior is not well understood.* -
- Researchers identified two distinct subtypes of retinoblastoma: Subtype 1 is characterized by early onset and less genetic alteration, while Subtype 2 has recurrent genetic changes, is less differentiated, and has a higher likelihood of spreading.* -
- Understanding these two subtypes can offer new insights into the biology and treatment of retinoblastoma, with subtype 1 being less aggressive and subtype 2 showing more aggressive traits and stem cell-like features.*
There is increasing evidence of the survival benefit of treating uveal melanoma in an early stage, however it is important to discuss with the patient the associated risk of visual loss. We investigated visual outcomes for uveal melanomas staged T1 (T1UM) treated by proton beam radiotherapy (PBR) as a function of their distance to fovea-optic disc. This retrospective study included a cohort of 424 patients with T1UM treated with PBR between 1991 and 2010 with at least a 5-year follow-up.
View Article and Find Full Text PDFPatients with liver metastases of uveal melanoma (LMUM) die from their metastatic evolution within 2 years. We established a nomogram to choose a treatment adapted to life expectancy. From 2002 to 2013, we reviewed 224 patients with LMUM selected by liver MRI.
View Article and Find Full Text PDFIntravitreal bevacizumab for neovascular glaucoma in uveal melanoma treated by proton beam therapy.
Graefes Arch Clin Exp Ophthalmol
February 2018
Background: To evaluate the efficacy of bevacizumab on reduction of the enucleation rate and control of intraocular pressure (IOP) in neovascular glaucoma (NVG)-complicating proton beam therapy for UM and to identify the determinants of the efficacy of bevacizumab.
Methods: Retrospective comparative study of patients with rubeosis following proton therapy for uveal melanoma. Patients were divided into two groups: a bevacizumab group and a control group which comprised two subgroups: panretinal photocoagulation (PRP)/cryotherapy and observation subgroups.
Fluorine 18 deoxyglucose positron emission tomography ((18)FDG PET) is widely used in staging of non-Hodgkin's lymphomas (NHL), but very few studies have focused on its role in the initial staging of patients with ocular adnexal lymphoma (OAL). The aim of this study was therefore to evaluate the role of (18)FDG PET in the diagnosis of ophthalmologic lymphoma. A retrospective review of all imaging records, including computed tomography (CT), magnetic resonance imaging (MRI), and FDG PET, was performed.
View Article and Find Full Text PDF